Differential subcellular p53 localization and function in N- and S-type neuroblastoma cell lines

Cell Growth and Differentiation

Volumn 9, Issue 7, 1998, Pages 545-555

  Isaacs, Jennifer S ^a,b   Hardman, Rebecca ^a   Carman, Teresa A ^c   Barrett, J Carl ^a,b,c   Weissman, Bernard E ^a,c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; CELL TYPE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION;

CELL LINE; CYTOPLASM; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; HUMANS; NEUROBLASTOMA; PHENOTYPE; SUBCELLULAR FRACTIONS; TELOMERASE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031846685     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Triche, T. J., Askin, F. B., and Kissane, J. M. Neuroblastoma, Ewing's sarcoma, and the differential diagnosis of small-, round-, blue-cell tumors. In: M. Finegold (ed.), Pathology of Neoplasia in Children and Adolescents, pp. 145-195. Philadelphia: W. B. Saunders, 1986.
2. Biedler, J. L., Roffler-Tarlov, S., Schachner, M., and Freedman, L. S. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res., 38: 3751-3757, 1978.
3. Thiele, C. J., McKeon, C., Triche, T. J., Ross, R. A., Reynolds, C. P., and Israel, M. A. Differential protooncogene expression characterizes histopathologically indistinguishible tumors of the peripheral nervous system. J. Clin. Invest., 80: 804-811, 1987.
4. Yeger, H., Mor, O., Pawlin, G., Kaplinsky, C., and Shiloh, Y. Importance of phenotypic and molecular characterization for identification of a neuroepithelioma tumor cell line, NUB-20. Cancer Res., 50: 2794-2802, 1990.
5. Pochedly, M. Histogenesis and histopathology of neuroblastoma. In: Neuroblastoma, Clinical and Biological Manifestations. New York: Elsevier Biomedical, 1982.
6. Russell, D. S., and Rubinstein, L. J. Peripheral tumors of the neurone series. In: Pathology of the Nervous System, pp. 305-323. Baltimore: Williams & Wilkins, 1971.
7. Biedler, J. L., Helson, L., and Spengler, B. A. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res., 33: 2643-2652, 1973.
8. Maeda, K., Feyles, V., McGarry, R. C., and Jery, L. M. Melanocytic differentiation of human neuroblastoma: expression of a human melanosome-associated antigen. J. Invest. Dermatol., 95: 665-670, 1990.
9. Ross, R. A., Spengler, B. A., and Biedler, J. L. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. Cancer Res., 71: 741-747, 1983.
10. Ciccarane, V., Spengler, B. A., Meyers, M. B., Biedler, J. L., and Ross, R. A. Phenotypic diversification in human neuroblastoma cells: expression of neural crest lineages. Cancer Res., 49: 219-225, 1989.
11. Sugimoto, T., Kato, T., Sawada, T., Horii, Y., Kemshead, J. T., Hino, T., Morioka, H., and Hosoi, H. Schwannian cell differentiation of human neuroblastoma cell lines in vitro induced by bromodeoxyuridine. Cancer Res., 48: 2531-2537, 1988.
12. Ross, R. A., Bossart, E., Spengler, B. A., and Biedler, J. L. Multipotent capacity of morphologically intermediate (I-type) human neuroblastoma cells after treatment with differentiation-inducing drugs. Adv. Neuroblastoma Res., 3: 193-201, 1991.
13. Dimitroulakos, J., Squire, J., Pawlin, G., and Yeger, H. NUB-7: a stable I-type human neuroblastoma cell line inducible along N- and S-type cell lineages. Cell Growth Differ., 5; 373-384, 1994.
14. Ross, R. A., Spengler, B. A., Domenech, C., Porubcin, M., Rettig, W. J., and Biedler, J. L. Human neuroblastoma I-type cells are malignant neural crest stem cells. Cell Growth Differ., 6: 449-456, 1995.
15. Ross, R. A., Spengler, B. A., Rettig, W. J., and Biedler, J. L. Differentiation-inducing agents stably convert human neuroblast I-type cells to neuroblast (N) or nonneuronal (S) neural crest cells. Prog. Clin. Biol. Res., 385: 253-259, 1994.
16. Tsokos, M., Scarpas, S., Ross, R. A., and Triche, T. J. Differentiation of human neuroblastoma recapitulates neural crest development. Am. J. Pathol., 128: 484-496, 1987.
17. Davidoff, A. M., Pence, J. C., Shorter, N. A., Inglehart, J. D., and Marks J. R. Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines. Oncogene, 7: 127-133, 1992.
18. Imamura, J., Bartram, C. R., Berthold, F., Harms, D., Nakamura, H., and Koeffler, P. Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification. Cancer Res., 53: 4053-4058, 1993.
19. Komuro, H., Hayashi, Y., Kawamura, M., Hayashi, K., Kaneko, Y., Kamoshita, S., Hanada, R., Yamamoto, K., Hongo, T., Yamada, M., and Tsuchida, Y. Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas. Cancer Res., 53: 5284-5288, 1993.
20. Bader, S. A., Fasching, C., Brodeur, G. M., and Stanbridge, E. J. Dissociation of suppression of tumorigenicity and differentiation in vitro effected by transfer of single human chromosomes into human neuroblastoma cells. Cell Growth Differ., 2: 245-255, 1991.
21. Moll, U. M., LaQuaglia, M., Benard, J., and Riou, G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl. Acad. Sci. USA, 92: 4407-4411, 1995.
22. Moll, U. M., Ostermeyer, A. G., Haladay, A. G., Windfield, B., Frazier, M., and Zambetti, G. Cytoplasmic sequestration of wild type p53 protein impairs the G1 checkpoint after DNA damage. Mol. Cell. Biol., 16: 1126-1137, 1996.
23. Isaacs, J. S., Chen, P., Garza, A., Hansen, M. F., Barrett, J. C., and Weissman, B. E. Failure of HPV E6 to rapidly degrade p53 in human HeLa × PNET cell hybrids. Oncogene, 14: 1669-1678, 1997.
24. Isaacs, J. S., Chiao, C., Merrick, B. A., Selkirk, J. K., Barrett, J. C., and Weissman, B. E. p53-dependent p21 induction following gamma-irradiation without concomitant p53 induction in a human peripheral neuroepithelial cell line. Cancer Res., 57: 2986-2992, 1997.
25. Kastan, M. B., Onyekwere, O., Estabrooks, L. L., and Wilson, S. J. Participation of p53 in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
26. Agarwal, M. L., Agarwal, A., Taylor, W. R., Wang, A-Q., Wagner, E. F., and Stark, G. R. Defective induction but normal activation and function of p53 in mouse cells lacking poly-ADP-ribose polymerase. Oncogene, 15: 1035-1041, 1997.
27. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D., Parsons, R., Trent, J. M., Lin, D., Mercer, E., Kinzler, K. W., and Vogelstein, B. WAF 1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
28. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclindependent kinases. Cell, 75: 805-816, 1993.
29. Xiong, Y., Hannon, H., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.
30. Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M., and Smith, J. R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res., 211: 701-704, 1994.
31. Atadia, P., Wong, H., Garkavtsev, I., Veillette, C., and Riabowol, K. Increased activity of p53 in senescing fibroblasts. Proc. Natl. Acad. Sci. USA, 92: 8348-8352, 1995.
32. Bond, J., Haughton, M., Blaydes, J., Gire, V., Wynford-Thomas, D., and Wyllie, F. Evidence that transcriptional activation by p53 plays a direct role in the induction of cellular senescence. Oncogene, 13: 2097-2104, 1996.
33. Sherwood, S. W., and Shimke, R. T. Cell cycle analysis of apoptosis using flow cytometry. Methods Cell Biol., 46: 77-97, 1995.
34. Shaulsky, G., Goldfinger, N., Ben-ze'ev, A., and Rotter, V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol. Cell. Biol., 70: 6565-7577, 1990.
35. Shaulsky, G., Goldfinger, N., Tosky, M. S., Levine, A. J., and Rotter, V. Nuclear localization is essential for the activity of p53 protein. Oncogene, 6: 2055-2065, 1991.
36. Masuda, H., Miller, C., Koeffler, H. P., Battifora, H., and Cline, M. J. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc. Natl. Acad. Sci. USA, 84: 7716-7719, 1987.
37. Blumenfeld, N., Gonen, H., Mayer, A., Smith, C. E., Siegel, N. R., Schwartz, A. L, and Ciechanover, A. Purification and characterization of a novel species of ubiqutin-carrier protein, E2, that is involved in degradation of non "n-end rule" protein substrates. J. Biol. Chem., 269: 9574-9581, 1994.
38. Chowdary, D. R., Dermody, J., Jha, K. K., and Ozer, H. L. Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol. Cell. Biol., 14: 1997-2003, 1994.
39. Cooper, M. J., Hutchins, M., Cohen, P. S., Helman, L. J., Mennie, R. J., and Israel, M. A. Human neuroblastoma tumor cell lines correspond to the arrested differentiation of chromaffin adrenal medullary neuroblasts. Cell Growth Differ., 1: 149-159, 1990.
40. Rettig, W. J., Spengler, B. A., Garin Chesa, P., Old, L. J., and Biedler, J. L. Coordinate changes in neuronal phenotype and surface antigen expression in human neuroblastoma cell variants. Cancer Res., 49: 1383-1389, 1987.
41. Dole, M. G., Jasty, R., Cooper, M. J., Thompson, C. B., Nunez, G. and Castle, V. P. Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res., 55: 2576-2582, 1995.
42. Gonzalez-Garcia, M., Garcia, I., Ding, L., O'Shea, S., Boise, L. H., Thompson, C. B., and Nunez, G. bcl-x is expressed in embryonic and postnatal neural tissues and functions to prevent neuronal cell death. Proc. Natl. Acad. Sci. USA, 92: 4304-4308, 1995.
43. Krajewski, S., Chatten, J., Hanada, M., and Reed, J. C. Immunohistochemical analysis of the bcl-2 oncoprotein in human neuroblastomas. Lab. Invest., 77: 42-54, 1995.
44. Reed, J. C., Meister, L., Tanaka, S., Cuddy, M., Yum, S., Geyer, C., and Pleasure, D. Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res., 51: 6529-6538, 1992.
45. Biedler, J. L., Spengler, B. A., Tien-ding, C., and Ross, R. A. Transdifferentiation of human neuroblastoma cells results in coordinate loss of neuronal and malignant properties. Prog. Clin. Biol. Res., 271: 265-276, 1988.
46. Spengler, B. A., Lazarova, D. L., Ross, R. A., and Biedler, J. L. Cell lineage and differentiation state are primary determinants of MYCN gene expression and malignant potential in human neuroblastoma cells. Oncol. Res., 9: 467-476, 1997.
47. Hastie, N. D., Dempster, M., Dunlop, M. G., Thompson, A. M., Green, D. K., and Allshire, R. C. Telomere reduction in human colorectal carcinoma and with ageing. Nature (Lond.), 346: 866-868, 1990.
48. Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, L., and Shay, J. W. Specific association of human telomerase activity with immortal cells and cancer. Science (Washington DC), 266: 2011-2015, 1994.
49. Vaziri, H., Dragowska, W., Allsopp, R. C., Thomal, T. E., Harley, C. B., and Lansdorp, P. M. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc. Natl. Acad. Sci. USA, 91: 9857-9860, 1994.
50. Albanell, J., Begona, W. H., Gunawardane, R., Scher, H. I., Dmitrovsky, E., and Moore, M. A. S. Telomerase activity is repressed during differentiation of maturation-sensitive but not resistant human tumor cell lines. Cancer Res., 56: 1503-1508, 1996.
51. Bestilny, L. J., Brown, C. B., Miura, Y., Robertson, L. D., and Reabowol, K. T. Selective inhibition of telomerase activity during terminal differentiation of immortal cell lines. Cancer Res., 56: 3796-3802, 1996.
52. Sharma, H. W., Sokoloski, J. A., Perez, J. R., Maltese, J. K., Sartorelli, A. C., Stein, C. A., Nichols, G., Khaled, Z., Telang, N. T., and Narayanan, R. Differentiation of immortal cells inhibits telomerase activity. Proc. Natl. Acad. Sci. USA, 92: 12343-12346, 1995.
53. Xu, D., Gruber, A., and Pisa, P. Suppression of telomerase activity in HL60 cells after treatment with differentiating agents. Leukemia (Baltimore), 10: 1354-1357, 1996.
54. Hiyama, E., Hiyama, K., Yokoyama, T., Matsuura, Y., Piatyszek, M. A., and Shay, J. W. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat. Med., 1: 249-255, 1995.
55. Kruk, P. A., Balajee, A. S., Rao, K. S., and Bohr, V. A. Telomere reduction and telomere inactivation during neuronal cell differentiation. Biochem. Biophys. Res. Commun., 224: 487-492, 1996.
56. Goldman, S. C., Chen, C-Y., Lansing, T. J., Gilmer, T. M., and Kastan, M. B. The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. Am. J. Pathol., 5: 1381-1385, 1996.
57. Moll, U. M., Riou, G., and Levine, A. J. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl. Acad. Sci. USA, 89: 7262-7266, 1992.
58. Gudas, J. M., Nguyen, H., Klein, R. C., Katayose, D., Seth, P., and Cowan, K. H. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. Clin. Cancer Res., 1: 71-80, 1995.
59. Tominaga, O., Hamelin, R., Trouvat, V., Salmon, R. J., Lesec, G., Thomas, G., and Remvikos, Y. Frequently elevated content of immunochemically defined wild-type p53 protein in colorectal adenomas. Oncogene, 8: 2653-2658, 1993.
60. Schlesinger, H. R., Rorke, L., Jamieson, R., and Hummeler, K. Neuronal properties of neuroextodermal tumors in vitro. Cancer Res., 41: 2573-2575, 1981.
61. Chen, C. Y., Oliner, J. D., Zhan, Q., Fornace, A. J., Jr., Vogelstein, B., and Kastan, M. B. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc. Natl. Acad. Sci. USA, 97: 2684-2688, 1994.
62. Momand, J., Zambetti, G. P., Olson, D., George, D.L., and Levine, A. J.. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69: 1237-1245, 1992.
63. Soddu, S., Blandino, G., Scardigli, R., Coen, S., Marchetti, A., Rizzo, M. G., Bossi, G., Cimino, L., Crescenzi, M., and Sacchi, A. Interference with p53 protein inhibits hematopoietic and muscle differentiation. J. Cell. Biol., 134: 193-204, 1996.
64. Fiddler, T. A., Smith, L., Tapscott, S. J., and Thayer, M. J. Amplification of MDM2 inhibits MyoD-mediated myogenesis. Mol. Cell. Biol., 16: 5048-5047, 1996.
65. Marshall, G. M., Cheung, B., Stacey, K. P., Camacho, M. L., Simpson, A. M., Kwan, E., Smith, S., Haber, M., and Norris, M. D. Increased retinoic acid receptor gamma expression suppresses the malignant phenotype and alters the differentiation potential of human neuroblastoma cells. Oncogene, 11: 485-491, 1995.
66. Grady, E. F., Schwab, M., and Rosenau, W. Expression of N-myc and c-src during the development of fetal human brain. Cancer Res., 47: 2931-2936, 1987.
67. Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., and Bishop, J. M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease state. Science (Washington DC), 224: 1121-1124, 1984.
68. Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., and Hammond, D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med., 313: 1111-1116, 1985.
69. Brodeur, G. M., and Nakagawara, A. Molecular basis of clinical heterogeneity in neuroblastoma. Am. J. Pediatr. Hemat. Oncol., 14: 111-116, 1992.
70. Biedler, J. L., Bossart, E., Ross, R. A., and Spengler, B. A. Loss of neuronal and malignant properties in transdifferentiated substrate-adherent (S-type) human neuroblastoma cells correlates with decreased MYCN expression. Proc. Am. Assoc. Cancer. Res., 33; 470, 1992.
71. Peverali, F. A., Orioli, D., Tonon, L., Ciana, P., Bunone, G., Negri, M., and Della-Valle, G. Retinoic acid-induced growth arrest and differentiation of neuroblastoma cells are countered by N-myc and enhanced by max overexpression. Oncogene, 12: 457-462, 1996.
72. Livingstone, L., White, A., Sprouse, J., Livanos, E., Jacks, T., and Tlsty, T. D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70: 923-935, 1992.
73. his). Oncogene, 12: 715-725, 1996.
74. Hiyama, K., Shinichi, I., Shirotani, Y., Inai, K., Hiyama, E., Murakami, I., Isobe, T., Inamizu, T., and Yamakido, M. Alterations in telomeric repeat length in lung cancer are associated with loss of heterozygosity in p53 and Rb. Oncogene, 10: 937-944, 1995.
75. Shay, J. W., Tomlinson, G., Piatyszek, M. A., and Gollahon, L. S. Spontaneous in vitro immortalization of breast epithelial cells from a patient with Li-Fraumeni syndrome. Mol. Cell. Biol., 75: 425-432, 1995.
76. Trojanowski, J. Q., Molenaar, W. M., Baker, D. L., Pleasure, D., and Lee, V. M-Y. Neural and neuroendocrine phenotype of neuroblastomas, ganglioneuro-blastomas, ganglioneuromas, and mature vs. embryonic human adrenal medullary cells. Adv. Neuroblastoma Res., 3: 335-351, 1991.
77. MacMillan, R. W., Blanc, W. B., and Santulli, T. V. Maturation of neuroblastoma to ganglioneuroma in lymph nodes. J. Pediatr. Surg., 11: 461-462, 1976.
78. Adam, A., and Hocholzer, L. Ganglioneuroblastoma of the posterior mediastinum. Cancer (Phila.), 47: 373-381, 1983.
79. Bolande, R. P. Spontaneous regression and cytodifferentiation of cancer in early life: the oncogenic grace period. Surv. Synth. Pathol. Res., 4: 296-311, 1985.
80. Tumilowicz, J. J., Nichols, W. W., Cholon, J. J., and Greene, A. E. Definition of a continuous human cell line derived from neuroblastoma. Cancer Res., 30: 2110-2118, 1970.
81. Ross, R. A., Joh, T. H., Reis, D. J., Spengler, B. A., and Biedler, J. L. Neurotransmitter-synthesizing enzymes in human neuroblastoma cells: relationship to morphological diversity. Adv. Neuroblastoma Res., 6: 151-160, 1980.